Chairman Wayne Channon is a successful entrepreneur with experience of managing high growth companies from start-up to exit. He has run companies in both Europe and the US. Wayne currently also chairs Cells4Life, the UK and Middle East leader in the cord blood stem cell storage segment. Amongst his companies, he founded ilion group plc which grew to be Europe’s second largest networking distributions group with revenues of €500 million, operating in nine countries. ilion was subsequently floated on the Official List of the London Stock Exchange. Wayne graduated from Imperial College with first class honors in mathematical physics.
Dr Jeff Drew
Chief Scientific Officer
Chief Scientific Officer Dr Jeff Drew is the founder of Stabilitech and the developer of the company’s proprietary technology. Jeff holds a degree in Microbiology and Virology from Manchester University, and a PhD in Molecular Virology from Reading University Institute of Animal Health at Pirbright, UK. Jeff has 18 years experience in microbiological, cancer, gene therapy and genetic research. His research has been conducted within various research institutes and departments in the UK including the Exotic Virus Research Laboratories at the Institute of Animal Health, Universities of Oxford, London, the Marie Curie Research Institute and the Chester Beatty Laboratories at the Institute of Cancer Research. He is the co-founder and a non-executive director of Cells4Life, a leading UK umbilical cord blood stem cell storage company.
Dr Elliot Bland
Business Development Director
Dr Elliot Bland is responsible for leading commercial activities on Stabilitech’s development pipeline and identifying new targets for Stabilitech’s novel oral vaccine platform. Formerly at Queen Mary Innovation Ltd, Elliot managed the commercialisation of life-science projects from Queen Mary University of London. Partnering with industry, he enabled the development and commercialisation of cutting edge science, generating revenues for the university and its inventors. He also produced non-clinical regulatory packages, preclinical toxicity plans and conducted scientific advice meetings with the MHRA. He now holds an honorary fellowship position at the university. Elliot was responsible for global business development at SLA Pharma Ltd, out-licensing a Phase III gastrointestinal treatment to a pan-European company. Previous to this, Elliot conducted innovation management & commercialisation for NHS trusts across London. Earlier in his career he held positions in a DNA diagnostic company and an AstraZeneca-SME partnership.
Prof Jeffrey Almond
Jeffrey Almond is a Visiting Professor at the Sir William Dunn School of Pathology, University of Oxford and at the Department of Microbiology, University of Reading. He is also an Oxford Martin Fellow with the Oxford Martin Programme on Vaccines. Previously (1999-2014) he was Vice President and Global Head of Research and External R&D at Sanofi Pasteur, the vaccine division of the Sanofi group, based in Lyon France. There he was responsible for a portfolio of vaccine projects across infectious diseases and cancer, and for establishing and managing R&D partnerships with Academia and Biotech companies relevant to the commercial interests of Sanofi Pasteur. Prior to joining Sanofi, Jeffrey Almond spent most of his career in the UK. He was lecturer at the University of Leicester from 1979-85 and Professor of Microbiology and Head of the School of Animal and Microbial Sciences at the University of Reading 1985-99. He has served on numerous national and international committees including being a member of Council of the MRC and the UK Spongiform Encephalopathies Advisory Committee. Previously he has held senior officer positions in several learned societies including the International Union of Microbiological Societies and the Academy of Medical Sciences. Professor Almond is currently chair of the Scientific Advisory Board of the Pirbright Institute and is a member of several scientific advisory boards both in the public and private sectors in Europe, the UK and the USA.
Dr Peter Cozens
Dr. Peter Cozens has worked for more than 30 years in the pharmaceutical industry, with broad international experience in both the biotechnology and conventional pharmaceutical sectors of the industry. In 1991 he joined Medeva PLC where he became Executive Vice President, Business Development and Intellectual Property, responsible for the building of Medeva’s development pipeline, managing its patents and trademark function and overseeing multinational patent litigation. Prior to Medeva he worked as a research scientist for Ciba-Geigy (now Novartis) and in R&D and business development at Wellcome (now GSK). He is currently a Partner at the consulting firm, ProPharma Partners Ltd., a member and former Chairman of the Intellectual Property Advisory Committee of the UK BioIndustry Association, a non-executive Director of Eden BioPharma Limited and non-executive chairman of Zysis Ltd
Non-executive director James Hudleston is an entrepreneur, corporate financier and highly successful investor in technology, biotechnology and the resource sector. He specialises in assisting management in the development, growth and exit of private and public companies. James is a keystone investor in Stabilitech and its largest shareholder. He also founded Hurricane Energy, a publicly quoted oil exploration, in 2004. Born and educated in Rhodesia, James is a St Radegund Fellow of Jesus College, Cambridge.
Non-Executive Director Myra Waiman is a biochemist and has worked in hospitals for a number of years before establishing Romney Consultants as a strategy and business consultancy. She has wide experience in medical device groups as well as biotech and other technical start-ups helping them fundraise and with business development. She is director of Westgate Hall Plc, non-executive director for various companies and is a trustee of Heart Cell Foundation, Weizmann Council UK and Prism The Gift fund.